Drug intelligence / Profile preview

CDI-873

Development stage: Preclinical
Lead developer: Cocrystal Pharma
Modality: Small Molecules
Administration: Oral

Overview

CDI-873 is a broad-spectrum oral antiviral drug candidate developed by Cocrystal Pharma for the treatment of COVID-19. It targets the SARS-CoV-2 main (3CL) protease, which is crucial for viral RNA replication. CDI-873 has shown superior _in vitro_ potency against SARS-CoV-2 and its variants, including Omicron, and exhibits a favorable safety profile and pharmacokinetic properties suitable for daily oral dosing[1][3][7].

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on CDI-873.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDI-873.

Explore the full profile